

Resource Summary Report

Generated by [RRID](#) on Aug 8, 2026

Response Evaluation Criteria in Solid Tumors

RRID:SCR_026435

Type: Tool

Proper Citation

Response Evaluation Criteria in Solid Tumors (RRID:SCR_026435)

Resource Information

URL: <https://recist.eortc.org/>

Proper Citation: Response Evaluation Criteria in Solid Tumors (RRID:SCR_026435)

Description: Provides methodology to evaluate activity and efficacy of new cancer therapeutics in solid tumors, using validated and consistent criteria to assess changes in tumor burden. RECIST Working Group comprises representatives of the European Organization for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) of the United States and Canadian Cancer Trials Group (CCTG), as well as several pharmaceutical companies. Its mission is to ensure that RECIST undergoes continued testing, validation and updating.

Abbreviations: RECIST

Resource Type: data or information resource

Keywords: new cancer therapeutics, evaluate activity and efficacy, solid tumors, response evaluation, criteria to assess changes in tumor burden,

Availability: Free, Freely available

Resource Name: Response Evaluation Criteria in Solid Tumors

Resource ID: SCR_026435

Record Creation Time: 20250219T060352+0000

Record Last Update: 20260808T190746+0000

Ratings and Alerts

No rating or validation information has been found for Response Evaluation Criteria in Solid Tumors.

No alerts have been found for Response Evaluation Criteria in Solid Tumors.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Fabi A, et al. (2026) Circulating tumor DNA and Response Evaluation Criteria In Solid Tumors: ctDNA-RECIST proof-of-concept in HER2-positive metastatic breast cancer. Journal of experimental & clinical cancer research : CR, 45(1).

Ahluwalia MS, et al. (2026) Efficacy and CNS Toxicity of Nivolumab and Ipilimumab in Rare Cancer Brain Metastases: A Multicenter Basket Trial Analysis (NCI/SWOG S1609). Clinical cancer research : an official journal of the American Association for Cancer Research, 32(10), 1928.

Lai J, et al. (2026) Flt3L-mediated tumor cDC1 expansion enhances immunotherapy by priming stem-like CD8+ T cells in lymph nodes. Nature immunology, 27(3), 530.

Ponz-Sarvisé M, et al. (2026) Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study. Cancer research communications, 6(3), 673.

Ramelyte E, et al. (2026) Circulating Tumor DNA Is Prognostic of Patient Outcome and Enables Therapy Monitoring in Metastatic Uveal Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(5), 970.

Hamid O, et al. (2025) First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(19), 4089.

Meric-Bernstam F, et al. (2025) Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors. Cancer research communications, 5(9), 1664.

Chen S, et al. (2023) Comprehensive analysis of glycoprotein VI-mediated platelet activation signaling pathway for predicting pan-cancer survival and response to anti-PD-1 immunotherapy. Computational and structural biotechnology journal, 21, 2873.

Huang S, et al. (2023) Downregulation of Claudin5 promotes malignant progression and radioresistance through Beclin1-mediated autophagy in esophageal squamous cell carcinoma. Journal of translational medicine, 21(1), 379.

Garajová I, et al. (2023) Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain? Life (Basel, Switzerland), 13(11).

Goetz MP, et al. (2023) Landscape of baseline and acquired genomic alterations in circulating tumor DNA with abemaciclib alone or with endocrine therapy in advanced breast cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*.